Date posted: 04-Aug-2017
Category: Press Releases
STV News visited our premises on Wednesday 2nd August to discuss NovaBiotics’ recently published work, describing how the novel antimicrobial peptide Luminaderm (NP108, derived from NovaBiotics proprietary peptide drug discovery platform) is highly effective in vitro against drug sensitive & drug resistant Staphylococcus aureus (MRSA & MSSA).
The report featured on the news bulletins that day and an excerpt can be viewed below
NovaBiotics Ltd
Cruickshank Building,
Craibstone,
Aberdeen,
AB21 9TR, UK
Tel:+44 (0)1224 711377
Registered Company
No. SC272344
NovaBiotics Inc
One Boston Place,
Suite 2600,
Boston
MA, 02108
Tel:+1 866 259 4527
NovaBiotics
90 Upper George's Street,
Dun Laoghaire,
Co. Dublin,
A96 R8R9
Tel:+353 1 2712605
Registered Company
No. 642058